Dennis N, Dunton K, Livings C, Bogoeva N, et al. Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial. Eur J Cancer 2024;217:115192.
PMID: 39798264